Ausgabe 7/2015
Inhalt (9 Artikel)
Population Pharmacokinetic/Pharmacodynamic Modelling of Dipeptidyl Peptidase IV Inhibitors
Cornelia B. Landersdorfer
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
Brian J. Kirby, William T. Symonds, Brian P. Kearney, Anita A. Mathias
Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature
Stefan Wolking, Elke Schaeffeler, Holger Lerche, Matthias Schwab, Anne T. Nies
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
Silke Retlich, Vincent Duval, Ulrike Graefe-Mody, Christian Friedrich, Sanjay Patel, Ulrich Jaehde, Alexander Staab
Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor
Sachiko Mita, Dan Meyers, Parasar Pal, TsuHan Lin, Tapan Majumdar, Sam Rebello, Gangadhar Sunkara, Jin Chen
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor
Masaru Hirano, Dan Meyers, GangaRaju Golla, Parasar Pal, Pascale Pinot, TsuHan Lin, Tapan Majumdar, Sam Rebello, Gangadhar Sunkara, Jin Chen
Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
Pieter M. M. De Kesel, Willy E. Lambert, Christophe P. Stove
Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement
Salmaan Kanji, Meghan Hayes, Adam Ling, Larissa Shamseer, Clarence Chant, David J. Edwards, Scott Edwards, Mary H. H. Ensom, David R. Foster, Brian Hardy, Tyree H. Kiser, Charles la Porte, Jason A. Roberts, Rob Shulman, Scott Walker, Sheryl Zelenitsky, David Moher